RAC conditionally approves lung cancer gene therapy.
作者信息
Jenks S
出版信息
J Natl Cancer Inst. 1994 Jul 6;86(13):964-5. doi: 10.1093/jnci/86.13.964.
PMID:8007017
Abstract
摘要
相似文献
1
RAC conditionally approves lung cancer gene therapy.美国放射学会有条件地批准肺癌基因疗法。
J Natl Cancer Inst. 1994 Jul 6;86(13):964-5. doi: 10.1093/jnci/86.13.964.
2
Gene therapy for lung cancer still on hold.肺癌基因治疗仍处于停滞状态。
J Natl Cancer Inst. 1994 Apr 6;86(7):486. doi: 10.1093/jnci/86.7.486.
3
Modification of mutant K-ras gene expression in non-small cell lung cancer (NSCLC).非小细胞肺癌（NSCLC）中突变型K-ras基因表达的修饰。
Hum Gene Ther. 1996 May 1;7(7):875-89. doi: 10.1089/hum.1996.7.7-875.
4
Gene therapy trial for lung cancer: caught between the RAC and a hard place.肺癌基因治疗试验：进退两难。
J Natl Cancer Inst. 1994 Mar 2;86(5):332-3. doi: 10.1093/jnci/86.5.332.
5
Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer.逆转录病毒介导的野生型p53基因向肺癌患者肿瘤的转移。
Nat Med. 1996 Sep;2(9):985-91. doi: 10.1038/nm0996-985.
6
Discussion.讨论。
J Thorac Cardiovasc Surg. 2012 Nov;144(5):1191. doi: 10.1016/j.jtcvs.2012.08.006.
7
FDA approves breakthrough immunotherapy for patients with non-small-cell lung cancer.美国食品药品监督管理局批准了用于非小细胞肺癌患者的突破性免疫疗法。
Cancer. 2017 Jan 1;123(2):191. doi: 10.1002/cncr.30524.
8
The targeted inhibitory effects of human amniotic fluid stem cells carrying CXCR4 promoter and DAL-1 on non-small cell lung carcinoma growth.携带CXCR4启动子和DAL-1的人羊水干细胞对非小细胞肺癌生长的靶向抑制作用。
Gene Ther. 2016 Feb;23(2):214-22. doi: 10.1038/gt.2015.90. Epub 2015 Aug 17.
9
Evaluation of an inhibitor of DNA methylation, 5-aza-2'-deoxycytidine, for the treatment of lung cancer and the future role of gene therapy.评估DNA甲基化抑制剂5-氮杂-2'-脱氧胞苷用于治疗肺癌及基因治疗的未来作用。
Adv Exp Med Biol. 2000;465:433-46. doi: 10.1007/0-306-46817-4_38.
10
Induction of cyclo-oxygenase-2 in non-small cell lung cancer cells by infection with DeltaE1, DeltaE3 recombinant adenovirus vectors.DeltaE1、DeltaE3重组腺病毒载体感染诱导非小细胞肺癌细胞中环氧化酶-2的表达。
Gene Ther. 2002 Jan;9(1):81-4. doi: 10.1038/sj.gt.3301621.
Zotero 插件